RALEIGH, N.C., May 20 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on the current issues facing adaptive, single-arm and Phase I/II designs in oncology trials on 26 May 2010 at 11:30 a.m. (EDT). One of PRA's oncology experts, John Constant, Ph.D., Vice President of Scientific Affairs, will be the presenter.
Dr. Constant will discuss how oncology trials continue to evolve and remain at the forefront of novel designs to handle cancer's extreme needs and historically toxic or complex therapies. The audio conference will review recent developments and issues in adaptive and small, efficient oncology designs, including highlights from the FDA's recently published draft guidance on this topic.
Dr. Constant has nearly 30 years of experience in applied statistics and pharmaceutical research. His oncology-specific experience encompasses design, analysis, reporting and regulatory agency representation and submissions in most major indications.
A recognized leader in oncology, hematology and supportive care, PRA has participated in more than 400 trials globally in every phase and virtually every oncology indication. Approximately 70% of PRA's therapeutic staff has oncology study experience, and our services have contributed to the approval of a number of leading and innovative cancer drugs.
For more information about this audio conference, navigate to www.praintl.com and click on "Events." To register, email [email protected]. The registration deadline is Tuesday, 25-May-2010.
About PRA International
PRA International conducts clinical trials in more than 75 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 37 global offices.
PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on-time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.
To learn more about PRA International, please visit www.PRAinternational.com, email [email protected] or call our Global Headquarters at +1 (919) 786-8200.
SOURCE PRA International
Advertisement
Dr. Constant will discuss how oncology trials continue to evolve and remain at the forefront of novel designs to handle cancer's extreme needs and historically toxic or complex therapies. The audio conference will review recent developments and issues in adaptive and small, efficient oncology designs, including highlights from the FDA's recently published draft guidance on this topic.
Advertisement
Dr. Constant has nearly 30 years of experience in applied statistics and pharmaceutical research. His oncology-specific experience encompasses design, analysis, reporting and regulatory agency representation and submissions in most major indications.
A recognized leader in oncology, hematology and supportive care, PRA has participated in more than 400 trials globally in every phase and virtually every oncology indication. Approximately 70% of PRA's therapeutic staff has oncology study experience, and our services have contributed to the approval of a number of leading and innovative cancer drugs.
For more information about this audio conference, navigate to www.praintl.com and click on "Events." To register, email [email protected]. The registration deadline is Tuesday, 25-May-2010.
About PRA International
PRA International conducts clinical trials in more than 75 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 37 global offices.
PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on-time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.
To learn more about PRA International, please visit www.PRAinternational.com, email [email protected] or call our Global Headquarters at +1 (919) 786-8200.
SOURCE PRA International
